Literature DB >> 16125926

Cancer staging and survival in colon cancer is dependent on the quality of the pathologists' specimen examination.

P Jestin1, L Påhlman, B Glimelius, U Gunnarsson.   

Abstract

Correct staging of colon cancer is decisive regarding further oncological treatment, surveillance and prediction of long-term survival. This study investigated the variability in accuracy of pathology reports with focus on differences between pathology departments and their compliance to regional guidelines. Data from the colon cancer register (1997-2002) of the Uppsala/Orebro, Sweden, health care region were analysed and the seven pathology departments in this region were compared. Included were 3735 patients who had undergone resection of a colon cancer. Cumulative 5-year survival was the main end-point. For 64% (n = 2390) of the cases, the number of lymph nodes examined was given (median 8). Survival in stage II was lower when fewer than 12 nodes were examined or when the number of nodes sampled was not given (P = 0.001, log-rank test). In stage III, those with at the most 3 nodes positive (N1) had a better survival than those with 4 or more nodes positive (N2) (P < 0.001, log-rank test). An index of metastases (IM), derived from the number of nodes with metastases divided by the number of nodes examined, was calculated for stage III tumours. Examination of 12 nodes is necessary to assure stage III cases with the median IM (0.32), whereas 20 nodes are necessary to assure 90% of cases with the lower quartile of IM (0.16). Irrespective of the number of nodes investigated, overall survival was better among patients with IM < 0.33 vs. IM > or = 33 (P < 0.001, log-rank test). The prognostic information of the IM was higher than that of the N-stage. Quality of a pathology department, measured by the median number of lymph nodes investigated and by the proportion of reports where the number is given, was determined to indicate correct staging and management of the patient. An index of metastases (IM) is a possible basis for guidance in the choice of adjuvant treatments that appears superior to that of N-stage.

Entities:  

Mesh:

Year:  2005        PMID: 16125926     DOI: 10.1016/j.ejca.2005.06.012

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  29 in total

1.  Pathological examination of 12 regional lymph nodes and long-term survival in stages I-III colon cancer patients: an analysis of 2,056 consecutive patients in two branches of same institution.

Authors:  Hong Hwa Chen; Dilip Chakravarty K; Jeng-Yi Wang; Chung-Rong Changchien; Reiping Tang
Journal:  Int J Colorectal Dis       Date:  2010-07-31       Impact factor: 2.571

2.  Sentinel Lymph Node Mapping with Isosulfan Blue or Indocyanine Green in Colon Cancer Shows Comparable Results and Identifies Patients with Decreased Survival: A Prospective Single-Center Trial.

Authors:  Benjamin Weixler; Andreas Rickenbacher; Dimitri Aristotle Raptis; Carsten T Viehl; Ulrich Guller; Jessica Rueff; Andreas Zettl; Markus Zuber
Journal:  World J Surg       Date:  2017-09       Impact factor: 3.352

3.  The impact of standard protocol implementation on the quality of colorectal cancer pathology reporting.

Authors:  Peter Ihnát; Patricie Delongová; Jaroslav Horáček; Lucia Ihnát Rudinská; Petr Vávra; Pavel Zonča
Journal:  World J Surg       Date:  2015-01       Impact factor: 3.352

4.  Factors affecting lymph node yield from patients undergoing colectomy for cancer.

Authors:  Zubin M Bamboat; Danielle Deperalta; Abdulmetin Dursun; David L Berger; Liliana Bordeianou
Journal:  Int J Colorectal Dis       Date:  2011-05-15       Impact factor: 2.571

5.  Does a laparoscopic approach affect the number of lymph nodes harvested during curative surgery for colorectal cancer?

Authors:  Galal El-Gazzaz; Tracy Hull; Jeffery Hammel; Daniel Geisler
Journal:  Surg Endosc       Date:  2009-06-11       Impact factor: 4.584

6.  Factors influencing lymph node harvest in colorectal surgery.

Authors:  M Gelos; J Gelhaus; P Mehnert; G Bonhag; M Sand; S Philippou; B Mann
Journal:  Int J Colorectal Dis       Date:  2007-09-07       Impact factor: 2.571

7.  Factors predicting worse prognosis in patients affected by pT3 N0 colon cancer: long-term results of a monocentric series of 137 radically resected patients in a 5-year period.

Authors:  Roberto Biffi; Edoardo Botteri; Emilio Bertani; Maria Giulia Zampino; Sabina Cenciarelli; Fabrizio Luca; Simonetta Pozzi; Maria Laura Cossu; Antonio Chiappa; Nicole Rotmensz; Barbara Bazolli; Elena Magni; Angelica Sonzogni; Bruno Andreoni
Journal:  Int J Colorectal Dis       Date:  2012-08-19       Impact factor: 2.571

8.  Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? The need for high quality pathology.

Authors:  Eva J A Morris; Nicola J Maughan; David Forman; Philip Quirke
Journal:  Gut       Date:  2007-05-09       Impact factor: 23.059

9.  Factors that influence 12 or more harvested lymph nodes in early-stage colorectal cancer.

Authors:  Chao-Wen Hsu; Chieh-Hsin Lin; Jui-Ho Wang; Hsin-Tai Wang; Wen-Chieh Ou; Tai-Ming King
Journal:  World J Surg       Date:  2009-02       Impact factor: 3.352

10.  Extended lymph node dissection in colorectal cancer surgery. Reliability and reproducibility in assessments of operative reports.

Authors:  Kjell Ovrebo; Ola Rokke
Journal:  Int J Colorectal Dis       Date:  2009-10-29       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.